Loading stock data…
Marker Therapeutics, Inc. (MRKR)
$1.28+0.10 (+8.47%)
Market ClosedLast close Sep 8
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Marker Therapeutics, Inc. in the Healthcare sector is trading at $1.28 with a market capitalization of $21M. Wall Street consensus targets $7.87 (3 analysts), implying a +514.6% move over the next 12 months. The stock is currently 48% below its 52-week high of $2.46, remaining 11.1% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +514.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.32M↓ | -$1.88M↑ | -$2.14M↑ | -$4.26M↓ | -$4.16M |
| Net Income | -$3.18M↓ | -$1.70M↑ | -$2.00M↑ | -$4.02M↑ | -$4.45M |
Peer Comparison
JNJUNHPFE
Fundamentals
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antige...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$21.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.53
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-71.57%
Volume
Today's trading volume
200,349
Recent News
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of +47.37% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Exploring 3 High Growth Tech Stocks in US Market
The United States market remained flat over the last week but has shown a strong performance with a 24% increase over the past year, and earnings are forecast to grow by 19% annually. In this context, identifying high growth tech stocks involves looking for companies that not only align with these optimistic earnings forecasts but also demonstrate robust innovation and adaptability in an ever-evolving industry landscape.
Exploring High Growth Tech Stocks In The US Market
Over the last 7 days, the United States market has seen a decline of 4.1%, yet it remains up by 21% over the past year with earnings projected to grow by 18% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that not only demonstrate robust innovation and scalability but also have strong fundamentals to navigate current market fluctuations.